SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:kth-217035"
 

Search: onr:"swepub:oai:DiVA.org:kth-217035" > Management of rivar...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates : a cohort study

Majeed, Ammar (author)
Agren, Anna (author)
Karolinska Institutet
Holmstrom, Margareta (author)
Karolinska Institutet
show more...
Bruzelius, Maria (author)
Karolinska Institutet
Chaireti, Roza (author)
Karolinska Institutet
Odeberg, Jacob, Professor, 1963- (author)
Karolinska Institutet,KTH,Science for Life Laboratory, SciLifeLab
Hempel, Eva-Lotta (author)
Magnusson, Maria (author)
Karolinska Institutet
Frisk, Tony (author)
Karolinska Institutet
Schulman, Sam (author)
show less...
 (creator_code:org_t)
AMER SOC HEMATOLOGY, 2017
2017
English.
In: Blood. - : AMER SOC HEMATOLOGY. - 0006-4971 .- 1528-0020. ; 130:15, s. 1706-1712
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) onrivaroxabanor apixaban. We investigated the effectiveness of PCCs given for the management of MBEs in patients on rivaroxaban or apixaban. Between 1 January 2014 and 1 October 2016, we prospectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs. The effectiveness of PCCs was assessed by using the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria for the assessment of the effectiveness of major bleeding management. The safety outcomes were thromboembolic events and all-cause mortality with in 30 days after treatmentwith PCCs. Atotal of 84 patients received PCCs for the reversal of rivaroxaban or apixaban due to a MBE. PCCs were given at amedian (interquartile range) dose of 2000 IU (1500-2000 IU). Intracranial hemorrhage (ICH) was themost common site of bleeding requiring reversal (n = 5 59; 70.2%), followed by gastrointestinal bleeding in 13 (15.5%) patients. Management with PCCs was assessed as effective in 58 (69.1%) patients and ineffective in 26 (30.9%) patients. Most patients with ineffective hemostasis with PCCs had ICH (n 5 16; 61.5%). Two patients developed an ischemic stroke, occurring 5 and 10 days after treatment with PCC. Twenty seven (32%) patients died within 30 days after a MBE. The administration of PCCs for the management of MBEs associated with rivaroxaban or apixaban is effective inmost cases and is associated with a low risk of thromboembolism. Our findings are limited by the absence of a control group in the study.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view